Bausch + Lomb Corporation BLCO on Thursday said it will discontinue development of BL1107 as a topical treatment for glaucoma ...

This medical stock is in the buy zone of a base. The glaucoma treatment developer raised its revenue forecast in its latest ...

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 3.8% in the afternoon session after the company announced its ...

Eyecare company Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to ...

Bausch + Lomb said on Thursday its glaucoma eye drop had missed ​the main goal in a mid-stage ‌trial of replicating visual function improvements observed in a smaller study.

Bausch + Lomb will stop developing a topical eye drop for glaucoma after the drug failed to meet its primary endpoint in a phase 2 study. The company on Thursday said the drug, BL1107, didn't ...

For the first time ever, scientists are attempting to reverse cellular aging in a living patient. The target: incurable vision loss. The risk: cancer.

Could this work to prevent blindness and eventually turn back the clock in other organs too?

From memorable patient encounters to emerging therapies, OT talks with practitioners about opportunities and challenges in ...

Glaucoma is a vision condition that results from damage to your optic nerve, often due to elevated pressure in the eye. It’s one of the most common causes of vision loss in adults and can lead to ...

The charity has encouraged optometrists to signpost eligible patients living with, or being monitored for, glaucoma to the ...

In glaucoma patients, sleeping with two stacked pillows was linked to slightly higher intraocular pressure (IOP) compared to sleeping with no pillows. The findings of the observational study ...